Your browser version may not work well with NCBI's Web applications. More information here...
1: Crit Care. 2005 Jun;9(3):257-8. Epub 2005 May 5.Click here to read Click here to read Links
Comment on:
Crit Care. 2005 Jun;9(3):R246-50.

Can mupirocin prevent methicillin-resistant Staphylococcus aureus infections?

Wertheim HF, Vos MC.

Department of Medical Microbiology and Infectious Disease, Erasmus MC, Rotterdam, The Netherlands. h.wertheim@erasmusmc.nl

In a retrospective study, Dr Muller and colleagues have assessed the efficacy of mupirocin nasal ointment alongside hygienic measures in methicillin-resistant Staphylococcus aureus (MRSA)-positive patients admitted to the intensive care unit (ICU). Their findings, which suggest that intranasal mupirocin can prevent ICU-related MRSA infections, need confirmation in a well-designed clinical trial. In general: early identification, isolation and treatment of all MRSA carriers, including health care workers, and disinfection of contaminated environments, are the main 'ingredients' of an effective MRSA 'search and destroy' program.

PMID: 15987417 [PubMed - indexed for MEDLINE]

PMCID: PMC1175903

Patient Drug Information

  • Mupirocin (Bactroban® , Bactroban® Nasal)

    Mupirocin, an antibiotic, is used to treat impetigo as well as other skin infections caused by bacteria. It is not effective against fungal or viral infections.

  • Source: AHFS Consumer Medication Information